cytarabine has been researched along with Communicable Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beverloo, HB; Cornelissen, JJ; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Kluin-Nelemans, HC; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, P; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Westveer, PH; Wijermans, PW; Willemze, R; Wittebol, S | 1 |
| Asou, N; Fujimoto, K; Hiraoka, A; Kobayashi, T; Kuriyama, K; Ohno, R; Saito, H; Tanimoto, M; Teshima, H; Yoshida, M | 1 |
2 trial(s) available for cytarabine and Communicable Diseases
| Article | Year |
|---|---|
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Communicable Diseases; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hematologic Tests; Humans; Imatinib Mesylate; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mortality; Piperazines; Pyrimidines | 2008 |
No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Japan Adult Leukemia Study Grou
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Mercaptopurine; Prednisolone; Recombinant Proteins; Recurrence; Remission Induction; Survival Analysis; Time Factors; Vincristine | 1993 |